QureGenAI Unveils Breakthroughs in Quantum-AI-Driven Drug Design at ISCA-QCCC 2025

Recently, the International Symposium on Computer Architecture (ISCA) and the 4th International Workshop on Quantum-Classical Co-Design of Computing (QCCC-25) were held in Tokyo, Japan. As the only Chinese team to deliver a contributed speech at this workshop, AceMapAI, in collaboration with China Pharmaceutical University and Ningbo Institute of Technology, presented their cutting-edge research achievements and technological breakthroughs in the field of quantum-classical hybrid computing to experts and scholars from top global academic institutions, industry, and national laboratories.

AceMapAI Chief Quantum Scientist Ian Zhi Yin, on behalf of the team, delivered a keynote speech titled "Application of SMILES-Inspired Quantum Operator Transfer Learning in Generative Quantum Eigensolvers." This research introduces for the first time a quantum operator representation transfer learning framework, utilizing AI technology to accelerate the design of quantum operator circuits, addressing complexity issues in solving the Schrödinger equation, and demonstrating the immense potential of combining AI with quantum computing, which received enthusiastic feedback from experts at the venue.

At this conference, AceMapAI also announced the upcoming release of TyxonQ, the next-generation quantum computing + AI drug design and development framework. TyxonQ aims to significantly enhance the practical application of quantum computing in fields such as drug discovery through its innovative classical-quantum hybrid architecture, optimized quantum compilation capabilities, and efficient cross-hardware facility scheduling. In particular, QureGenAI, the platform built on TyxonQ, has started offering SaaS services and MCP services for large model integration globally, showcasing AceMapAI's leadership in advancing the practical application of quantum computing.

In addition, AceMapAI showcased its AMB-HAE androgenetic alopecia treatment drug pipeline, which utilizes the key TyxonQ technology, now entering the pre-IND research stage. It also launched the world's first quantum-AI Raman spectroscopy system for rapid quantitative modeling of Raman signal characteristics of hard-to-obtain pure substances. These achievements signify that AceMapAI is not only playing a crucial role in the global quantum technology revolution but also pioneering the definition of collaborative paradigms and industrial implementation standards.

As quantum computing reaches a pivotal turning point toward practical application, AceMapAI's outstanding performance at ISCA and QCCC-2025 demonstrates that China is ushering in an era of "computable life," bringing new hope and possibilities to the health industry both in China and globally. AceMapAI’s co-founder and CEO, Li Xiaoran, stated that the company will continue to push forward in the field of quantum computing for drug discovery combined with AI design. Using this conference as an opportunity, the company will further strengthen cooperation with all parties, continuously explore the deep integration boundaries of quantum computing and AI in drug design, improve the construction of the artificial intelligence drug design platform QureGenAI (formerly known as AceMapAI), and accelerate the delivery of a globally competitive new drug pipeline.